<DOC>
	<DOCNO>NCT01383733</DOCNO>
	<brief_summary>This multicenter , open-label , multiple ascend dose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics efficacy RO5458640 patient advance solid tumor . Cohorts patient receive ascend dos RO5458640 intravenously , either weekly every 2 week every 3 week , disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5458640 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm malignant solid tumor Measurable and/or evaluable disease accord RECIST 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver renal function Prior chemotherapy , radiotherapy , hormonal therapy cancer within 3 week first study treatment , except short course palliative radiotherapy pain Antibody therapy immunotherapy currently less 21 day prior study treatment Current immunosuppressive therapy , include prescribe organ transplantation rheumatologic disease Corticoid therapy &gt; 10 mg/day prednisone equivalent Patients recover &gt; grade 1 ( NCI CTCAE ) prior adverse event cancer therapy , except alopecia Pregnant breastfeeding woman Known hypersensitivity component RO5458640 previous severe hypersensitivity reaction monoclonal antibody therapy History active seizure disorder History CNS leptomeningeal metastasis , except clinically stable disease least 3 week prior first study drug Cardiovascular illness : CVA MI &lt; 6 month prior study , CHF &gt; NYHA Class 2 , QTcF &gt; 480 msec . Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>